This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Influenza	Influenza matrix protein 2 extracellular domain (M2e)	<p>A study in mice identified human anti-M2e mAbs that could help treat influenza. In a mouse model of lethal influenza infection, either of two anti-M2e mAbs increased survival against multiple viral strains compared with control mAb or vehicle. Both mAbs bound to an N-terminal segment of M2e that is highly conserved across multiple influenza strains. Ongoing studies are evaluating the lead anti-M2e mAb, TCN-032 from Theraclone Sciences Inc., in a ferret model of influenza infection.</p> <p>Dynavax Technologies Corp. has a universal flu vaccine using an immunostimulatory sequence linked to a nucleoprotein (NP) and M2e in preclinical development.</p> <p>SciBX 3(27); doi:10.1038/scibx.2010.831 Published online July 15, 2010</p>	Patent application filed; licensed to Zenyaku Kogyo Co. Ltd. in Japan; available for licensing outside Japan	<p>Granda III, A.G. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 28, 2010; doi:10.1073/pnas.0911806107</p> <p>Contact: Matthew Moyle, Theraclone Sciences Inc., Seattle, Wash. e-mail: mmoyl@theraclon-scicncs.com</p>